Results of a new study point to a link between exposure to tamoxifen and aromatase inhibitors and reduced diagnoses of neurodegenerative diseases, particularly Alzheimer’s disease, in women with breast cancer. The findings were published in JAMA Network Open.
For the retrospective analysis, the researchers used the Humana claims data set from January 1, 2007 to March 31, 2017. The data set contains claims from private payer and Medicare insurance data sets from across the United States, but primarily in the southeast.
The authors identified information from nearly 58,000 women with breast cancer aged 45 or older. All had been actively enrolled in Human claims records for 6 months before and at least 3 years after their diagnoses.
To determine the association between hormone-modulating therapy and diagnosis of neurodegenerative disease, a survival analysis was conducted. A propensity score approach was used to minimize measured and umeasured selection bias.